Transmission of HIV-1 with drug resistance mutations (DRMs) in Spain remains stable around 13%. However, the profile of recent HIV-1 seroconverters has experienced significant changes.
Retrospective analyses of all individuals with HIV-1 infection acquired within the past 12 months recruited at a national registry since year 1997.
A total of 1032 recent HIV-1 seroconverters were examined (92.2% men; median age 31 years; 84% homosexual men). At the moment of diagnosis, median plasma HIV-RNA and CD4+ cell counts were 4.5 log copies/ml and 558 cells/μl, respectively. A total of 136 individuals (13.8%) carried non-B subtypes. Major primary DRMs were found in 13.4%, being 7.7% for nucleoside reverse transcriptase inhibitor (NRTI), 5.8% for nonnucleoside reverse transcriptase inhibitor (NNRTI) and 2.9% for protease inhibitor. NRTI DRM significantly declined from 23.7% in 1997–2000 to 5.7% in 2010–2012 (P < 0.01). Overall, X4 viruses were found in 19.7% of HIV-1 seroconverters, increasing from 11.5% before 2001 to 23.3% since year 2010 (P = 0.04). Interestingly, median CD4+ cell counts were significantly lower in seroconverters diagnosed during the last period after adjusting for potential confounders. In multivariate analyses, X4 tropism, high HIV-RNA, foreigners and non-B subtypes were independent predictors of lower CD4+ cell counts.
Transmission of NRTI DRM has declined significantly in recent HIV-1 seroconverters in Spain. Conversely, X4 tropic viruses are on the rise and currently account for 23.3% of new HIV-1 infections. These individuals present with lower CD4+ cell counts suggesting that circulating HIV-1 strains might have gained virulence.
aHospital Carlos III
bCentro Sanitario Sandoval, Madrid
cHospital Conxo-CHUS, Santiago
dHospital General, Elche & Universidad Miguel Hernández, Alicante
eHospital Rio Hortega, Valladolid
fHospital Vall d’Hebron, Barcelona
gHospital Universitario Puerta de Hierro & Puerta de Hierro Research Institute, Madrid, Spain.
Correspondence to Dr Carmen de Mendoza, Department of Internal Medicine, Hospital Universitario Puerta de Hierro & Puerta de Hierro Research Institute, Calle Joaquin Rodrigo 2, Majadahonda 28222, Madrid, Spain. E-mail: email@example.com
Received 21 December, 2013
Revised 24 February, 2014
Accepted 24 February, 2014
This work was presented orally at the International Workshop on HIV & Hepatitis Virus Drug Resistance and Curative Strategies, which was held in Toronto, Canada, on 4–8 June 2013 (abstract #14).